Breakdown | |||||
TTM | Mar 2024 | Mar 2023 | Dec 2020 | Dec 2019 | Dec 2018 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
16.25M | 5.83M | -105.40M | 101.98M | 60.29M | 79.47M | Gross Profit |
3.41M | -89.30M | -150.93M | 81.20M | 60.29M | 75.80M | EBIT |
-65.22M | -2.74B | -253.17M | -47.41M | -135.38M | 41.44M | EBITDA |
23.38M | -2.74B | -234.09M | -13.81M | -135.05M | 41.68M | Net Income Common Stockholders |
-547.80M | -2.66B | -130.98M | -58.04M | -334.04M | -5.01M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
7.98M | 7.98M | 8.73M | 12.49M | 17.55M | 3.54M | Total Assets |
368.50M | 368.50M | 2.91B | 2.82B | 2.68B | 2.08B | Total Debt |
120.50M | 2.20M | 52.13M | 180.08M | 321.80M | 378.12M | Net Debt |
112.53M | -5.78M | 43.40M | 167.59M | 304.25M | 374.58M | Total Liabilities |
309.57M | 3.00K | 1.02B | 282.84M | 441.08M | 690.86M | Stockholders Equity |
-234.35M | 368.50M | 1.93B | 2.53B | 563.97M | 320.46M |
Cash Flow | Free Cash Flow | ||||
-51.86M | -59.98M | -97.19M | -57.23M | -54.17M | 17.44M | Operating Cash Flow |
-50.12M | -58.22M | -95.12M | -54.01M | -51.19M | 17.81M | Investing Cash Flow |
29.48M | 44.06M | 63.02M | -5.98M | 70.44M | 141.54M | Financing Cash Flow |
23.02M | 12.59M | -34.46M | 43.86M | -5.24M | -156.36M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
78 Outperform | $71.43B | 17.47 | 28.29% | 1.46% | -20.40% | -13.30% | |
74 Outperform | $154.99B | 35.12 | 34.07% | 3.03% | 21.25% | 97.42% | |
69 Neutral | $91.82B | 31.15 | 13.23% | 0.68% | 42.19% | -18.20% | |
67 Neutral | $12.73B | 12.71 | 18.90% | 3.97% | 62.87% | ― | |
67 Neutral | $44.55B | 68.20 | 15.93% | 2.77% | 6.12% | -15.84% | |
63 Neutral | $12.75B | 9.36 | 8.64% | 84.32% | 13.82% | -3.89% | |
31 Underperform | $2.48M | ― | -538.85% | ― | 78.84% | 97.65% |
On April 4, 2025, Beneficient closed a $9.6 million primary capital transaction with Pulse Pioneer Fund, LP, marking its first GP Primary transaction of the fiscal year. This transaction, involving the issuance of Series B-6 Resettable Convertible Preferred Stock, is expected to enhance the collateral for Beneficient’s ExAlt loan portfolio by approximately $9.6 million. The company believes this move will drive shareholder value and support its strategic vision and growth objectives, as it continues to address the significant demand for primary commitments in the alternative asset market.
On March 10, 2025, Beneficient announced a binding agreement to settle all claims in the GWG Litigation, which involved lawsuits in federal and bankruptcy courts in Texas against the company and its directors. The settlement, pending court approval, resolves claims without admission of fault and will be funded by insurance. This move aims to eliminate litigation costs and allow the company to focus on its business strategy, although other related claims remain outstanding.
Beneficient has prepared an investor presentation for its upcoming appearance at the Sequire Investor Summit on January 22, 2025. The presentation contains summary information aligned with the company’s filings with the Securities and Exchange Commission, and will be used to provide context during public announcements. Beneficient does not commit to updating the presentation publicly unless deemed necessary by management.